Published in Pharmacoeconomics on January 01, 2001
Cost effectiveness analysis in health care: contraindications. BMJ (2002) 1.80
Cost-effectiveness of a telephone-delivered intervention for physical activity and diet. PLoS One (2009) 1.19
Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res (2008) 1.05
Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action. Healthc Policy (2010) 0.87
Coping with uncertainty on health decisions: assessing new solutions. Eur J Health Econ (2012) 0.83
Budget impact analysis of switching to digital mammography in a population-based breast cancer screening program: a discrete event simulation model. PLoS One (2014) 0.83
Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ (2011) 0.82
The business case for preconception care: methods and issues. Matern Child Health J (2006) 0.81
Cost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients. PLoS One (2009) 0.81
"Budget impact analyses": a practical policy making tool for drug reimbursement decisions. Iran J Pharm Res (2014) 0.81
Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer (2008) 0.79
Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatry Ment Health (2007) 0.79
Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain. Health Econ Rev (2012) 0.77
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain. Health Econ Rev (2013) 0.77
Clinical Practice Variation Needs to be Considered in Cost-Effectiveness Analyses: A Case Study of Patients with a Recent Transient Ischemic Attack or Minor Ischemic Stroke. Appl Health Econ Health Policy (2016) 0.75
Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes population. Vasc Health Risk Manag (2007) 0.75
The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program. Hum Vaccin Immunother (2015) 0.75
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Health Econ Rev (2015) 0.75
The use of economic evaluation in CAM: an introductory framework. BMC Complement Altern Med (2010) 0.75
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer (2009) 0.75
Budget impact from the incorporation of positron emission tomography - computed tomography for staging lung cancers. Rev Saude Publica (2015) 0.75
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. Pharmacoeconomics (2017) 0.75
General practice fundholding. BMJ (1990) 6.43
Sequence and domain relationships of ntrC and nifA from Klebsiella pneumoniae: homologies to other regulatory proteins. EMBO J (1986) 5.20
One hundred questions of importance to the conservation of global biological diversity. Conserv Biol (2009) 3.95
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med (1999) 3.53
Positive control and autogenous regulation of the nifLA promoter in Klebsiella pneumoniae. Nature (1983) 3.43
Effectiveness, efficiency, and NICE. BMJ (2001) 3.03
A framework for clinical evaluation of diagnostic technologies. CMAJ (1986) 2.26
Some guidelines on the use of cost effectiveness league tables. BMJ (1993) 2.16
Results of selective early operation in myelomeningocele. Arch Dis Child (1973) 2.12
When is it cost-effective to change the behavior of health professionals? JAMA (2001) 2.08
Evidence for a complex regulatory array in the first intron of the human adenosine deaminase gene. Genes Dev (1989) 1.93
The pharmaceutical industry and health reform: lessons from Europe. Health Aff (Millwood) (1994) 1.81
Efficiency in the National Health Service: lessons from abroad. Health Policy (1988) 1.79
Should clinical trials with concurrent economic analyses be blinded? JAMA (1997) 1.76
A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut (2001) 1.72
Sequence and molecular analysis of the nifL gene of Azotobacter vinelandii. Mol Microbiol (1993) 1.69
Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess (2005) 1.64
Reporting guidelines for economic studies. Health Econ (1995) 1.62
Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer (2006) 1.57
The effect on the function of the transcriptional activator NtrC from Klebsiella pneumoniae of mutations in the DNA-recognition helix. Nucleic Acids Res (1988) 1.54
The economics of femorocrural reconstruction for critical leg ischemia with and without autologous vein. J Vasc Surg (1992) 1.51
Absence of DNA sequences homologous to transposable element Tn5 (Kan) in the chromosome of Escherichia coli K-12. J Bacteriol (1978) 1.49
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess (2006) 1.49
The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics (1994) 1.48
Desk top analysers in general medical practice: how useful are they? Med Lab Sci (1990) 1.48
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer (2005) 1.48
Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia. Br J Obstet Gynaecol (1993) 1.47
Guidelines for the clinical and economic evaluation of health care technologies. Soc Sci Med (1986) 1.47
Cost-of-illness studies: a major headache? Pharmacoeconomics (1992) 1.44
A randomized trial of Evidence-based OutReach (EBOR): rationale and design. Control Clin Trials (1999) 1.42
Systematic review of utilities in abdominal aortic aneurysm. Eur J Vasc Endovasc Surg (2008) 1.42
Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet. JAMA (1998) 1.42
Paradoxical reaction of blood pressure on sleep apnoea patients treated with Positive Airway Pressure. Rev Port Pneumol (2011) 1.39
In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J Clin Invest (1995) 1.36
The product of the nitrogen fixation regulatory gene nfrX of Azotobacter vinelandii is functionally and structurally homologous to the uridylyltransferase encoded by glnD in enteric bacteria. J Bacteriol (1991) 1.28
Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab (2006) 1.27
A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke (2001) 1.27
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther (2002) 1.27
Comparison of alternative sources of data on health service encounters. J Health Serv Res Policy (1999) 1.25
The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy (1997) 1.23
Stapled haemorrhoidectomy (haemorrhoidopexy) for the treatment of haemorrhoids: a systematic review and economic evaluation. Health Technol Assess (2008) 1.22
Nutrition economics - characterising the economic and health impact of nutrition. Br J Nutr (2010) 1.14
Redundancy of the conserved His residue in Azotobacter vinelandii NifL, a histidine autokinase homologue which regulates transcription of nitrogen fixation genes. Mol Microbiol (1994) 1.14
Prevalence of new-onset insomnia in patients with obstructive sleep apnoea syndrome treated with nocturnal ventilatory support. Rev Port Pneumol (2011) 1.12
European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care. Eur J Cancer (1995) 1.12
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol (2004) 1.12
Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics (2001) 1.11
Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Econ (1992) 1.09
An economic evaluation of transcervical endometrial resection versus abdominal hysterectomy for the treatment of menorrhagia. Br J Obstet Gynaecol (1993) 1.09
16-aryloxyprostaglandins: a new class of potent luteolytic agent. Prostaglandins (1974) 1.08
Control of Herbaspirillum seropedicae NifA activity by ammonium ions and oxygen. J Bacteriol (1999) 1.07
Resource costing for multinational neurologic clinical trials: methods and results. Health Econ (1998) 1.06
Cost-effectiveness analysis comparing epidural, patient-controlled intravenous morphine, and continuous wound infiltration for postoperative pain management after open abdominal surgery. Br J Anaesth (2012) 1.05
The U.K. NHS economic evaluation database. Economic issues in evaluations of health technology. Int J Technol Assess Health Care (2000) 1.04
A systematic review of the effectiveness and cost-effectiveness of different models of community-based respite care for frail older people and their carers. Health Technol Assess (2007) 1.03
Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes (2001) 1.03
Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia (2005) 1.02
Translation of Berlin Questionnaire to Portuguese language and its application in OSA identification in a sleep disordered breathing clinic. Rev Port Pneumol (2011) 1.01
Economic evaluation of healthcare: a half-way technology. Health Econ (1994) 1.01
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs (1998) 1.00
Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia (2012) 1.00
Pharmacoeconomics: integrating economic evaluation into clinical trials. Br J Clin Pharmacol (1997) 0.99
Isolation and sequence analysis of cDNA for rat carboxypeptidase E [EC 3.4.17.10], a neuropeptide processing enzyme. Mol Endocrinol (1989) 0.98
Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax (2001) 0.97
The identification of bias in studies of the diagnostic performance of imaging modalities. Br J Radiol (1997) 0.97
Two-hybrid analysis of domain interactions involving NtrB and NtrC two-component regulators. Mol Microbiol (2001) 0.96
Identifying studies for systematic reviews. An example from medical imaging. Int J Technol Assess Health Care (2000) 0.95
Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol (2001) 0.94
Positional requirements for the function of nif-specific upstream activator sequences. Mol Gen Genet (1987) 0.93
One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart (2004) 0.92
Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J (1990) 0.92
Calcium accumulation and cyclic AMP-stimulated phosphorylation in plasma membrane-enriched preparations of myocardium. Arch Biochem Biophys (1976) 0.92
Workshop Report: concepts and methods in the economics of nutrition--gateways to better economic evaluation of nutrition interventions. Br J Nutr (2012) 0.91
The basis of ammonium release in nifL mutants of Azotobacter vinelandii. J Bacteriol (1999) 0.90
A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. Health Policy (1999) 0.90
The DH register of cost-effectiveness studies: content and quality. Health Trends (1995) 0.90
Does expenditure on pharmaceuticals give good value for money?: current evidence and policy implications. Health Policy (1993) 0.88
A nice challenge for health economics. Health Econ (2000) 0.88
Comparison of a complement fixation test, a gel diffusion test and two absorbed and unabsorbed ELISAs for the diagnosis of paratuberculosis in sheep. Vet Microbiol (1994) 0.88
Folic acid supplements to prevent neural tube defects: trends in East of Ireland 1996-2002. Ir Med J (2004) 0.88
Domiciliary physiotherapy for old people who have fallen. Int Rehabil Med (1983) 0.88
Spina bifida as an obstetric problem. Dev Med Child Neurol Suppl (1970) 0.87
Properties of the Escherichia coli rhodanese-like protein SseA: contribution of the active-site residue Ser240 to sulfur donor recognition. FEBS Lett (2001) 0.87
Chimeric transcriptional activators generated in vivo from VnfA and AnfA of Azotobacter vinelandii: N-terminal domain of AnfA is responsible for dependence on nitrogenase Fe protein. J Bacteriol (1994) 0.87
Health economics: an introduction for clinicians. Ann Intern Med (1987) 0.86
Systematic review of endoscopic ultrasound in gastro-oesophageal cancer. Health Technol Assess (1998) 0.86
A comparison of the cost-effectiveness of stroke care provided in London and Copenhagen. Int J Technol Assess Health Care (2000) 0.85
Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness. Health Technol Assess (2000) 0.85
Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology. J Rheumatol (1999) 0.85
Cloning, sequence analysis and overexpression of the rhodanese gene of Azotobacter vinelandii. Eur J Biochem (1996) 0.84
Palliative radiotherapy--counting the costs of changing practice. Health Policy (1991) 0.84
Utility of health states in chronic kidney disease: a structured review of the literature. Curr Med Res Opin (2008) 0.84
Acceptance for chronic dialysis treatment: insufficient and unequal. Nephrol Dial Transplant (1996) 0.84
Erectile dysfunction in obstructive sleep apnea syndrome--prevalence and determinants. Rev Port Pneumol (2012) 0.83
Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics (1999) 0.83
A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics (1992) 0.82
The economic evaluation of cancer treatments and programmes. Eur J Cancer (1991) 0.82